#BEGIN_DRUGCARD DB01713

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C14H22N2O16P2

# Chemical_IUPAC_Name:
[({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy})phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
The decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Udp-Alpha-D-Xylopyranose

# HET_ID:
UDX

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C14H22N2O16P2/c17-5-3-28-13(11(22)8(5)19)31-34(26,27)32-33(24,25)29-4-6-9(20)10(21)12(30-6)16-2-1-7(18)15-14(16)23/h1-2,5-6,8-13,17,19-22H,3-4H2,(H,24,25)(H,26,27)(H,15,18,23)/t5-,6-,8-,9-,10+,11+,12+,13-/m0/s1

# InChI_Key:
InChIKey=DQQDLYVHOTZLOR-NNFAFSNNSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1713

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
536.2758

# Molecular_Weight_Mono:
536.04445569

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1DLI

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.3

# Predicted_LogS:
-1.6

# Predicted_Water_Solubility:
1.36e+01 g/l

# Primary_Accession_No:
DB01713

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936197

# PubChem_Substance_ID:
46508749

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03173

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@H]1[C@H](CO[P@](O)(=O)O[P@@](O)(=O)O[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O)O[C@H]([C@@H]1O)N1C=CC(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:25 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L08444

# Drug_Target_1_GenBank_ID_Protein:
295189

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
hasB

# Drug_Target_1_Gene_Sequence:
>1209 bp
ATGAAAATAGCAGTTGCTGGATCAGGATATGTTGGATTATCACTAGGAGTTCTTTTATCA
CTTCAAAACGAAGTCACTATTGTTGATATTCTTCCCTCTAAAGTTGATAAGATTAATAAT
GGCTTATCACCAATTCAAGATGAATATATTGAATATTACTTAAAAAGTAAGCAATTATCT
ATTAAAGCAACTTTAGATAGCAAAGCAGCTTATAAAGAAGCGGAACTGGTCATTATTGCC
ACACCTACAAATTACAACAGTAGAATTAATTATTTTGATACACAGCATGTTGAAACAGTT
ATCAAAGAGGTACTAAGCGTTAATAGCCATGCAACTCTTATCATCAAATCAACAATTCCA
ATAGGTTTCATTACTGAAATGAGACAGAAATTCCAAACTGATCGTATTATCTTCAGCCCT
GAATTTTTAAGAGAATCTAAAGCTTTATATGACAACTTATATCCAAGCCGAATTATTGTT
TCTTGTGAAGAAAACGATTCTCCAAAAGTAAAGGCAGACGCAGAAAAATTTGCACTTTTA
TTAAAGTCTGCAGCTAAAAAAAATAATGTACCAGTACTTATTATGGGAGCTTCAGAAGCT
GAAGCAGTAAAACTATTTGCCAATACTTATTTAGCGTTAAGGGTAGCTTATTTTAATGAG
TTAGACACTTACGCAGAATCGAGAAAATTAAATAGTCACATGATTATTCAAGGAATTTCT
TATGATGATCGAATAGGAATGCATTATAATAACCCATCATTTGGTTATGGAGGTTATTGT
CTACCTAAAGATACGAAGCAATTATTGGCAAATTACAATAATATTCCCCAAACACTAATT
GAAGCTATCGTTTCATCAAATAATGTGCGCAAGTCCTATATTGCTAAGCAAATTATCAAC
GTCTTAAAAGAGCAGGAGTCCCCAGTAAAAGTAGTCGGGGTTTACCGTTTAATTATGAAA
AGTAACTCAGATAACTTTAGAGAAAGTGCTATCAAAGATGTTATTGACATTCTTAAAAGT
AAAGACATTAAGATAATTATTTATGAGCCAATGTTAAACAAACTTGAATCTGAAGATCAA
TCTGTACTTGTAAATGATTTAGAGAATTTCAAGAAACAAGCAAATATTATCGTAACTAAT
CGCTATGATAATGAATTACAAGATGTTAAAAATAAAGTTTACAGTAGAGATATTTTTGGT
AGAGACTAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
10841783	Campbell RE, Mosimann SC, van De Rijn I, Tanner ME, Strynadka NC: The first structure of UDP-glucose dehydrogenase reveals the catalytic residues necessary for the two-fold oxidation. Biochemistry. 2000 Jun 13;39(23):7012-23.
8463246	Dougherty BA, van de Rijn I: Molecular characterization of hasB from an operon required for hyaluronic acid synthesis in group A streptococci. Demonstration of UDP-glucose dehydrogenase activity. J Biol Chem. 1993 Apr 5;268(10):7118-24.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3672

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
45484

# Drug_Target_1_Name:
UDP-glucose 6-dehydrogenase

# Drug_Target_1_Number_of_Residues:
402

# Drug_Target_1_PDB_ID:
1DLI

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00984	UDPG_MGDP_dh
PF03720	UDPG_MGDP_dh_C
PF03721	UDPG_MGDP_dh_N

# Drug_Target_1_Protein_Sequence:
>UDP-glucose 6-dehydrogenase
MKIAVAGSGYVGLSLGVLLSLQNEVTIVDILPSKVDKINNGLSPIQDEYIEYYLKSKQLS
IKATLDSKAAYKEAELVIIATPTNYNSRINYFDTQHVETVIKEVLSVNSHATLIIKSTIP
IGFITEMRQKFQTDRIIFSPEFLRESKALYDNLYPSRIIVSCEENDSPKVKADAEKFALL
LKSAAKKNNVPVLIMGASEAEAVKLFANTYLALRVAYFNELDTYAESRKLNSHMIIQGIS
YDDRIGMHYNNPSFGYGGYCLPKDTKQLLANYNNIPQTLIEAIVSSNNVRKSYIAKQIIN
VLKEQESPVKVVGVYRLIMKSNSDNFRESAIKDVIDILKSKDIKIIIYEPMLNKLESEDQ
SVLVNDLENFKKQANIIVTNRYDNELQDVKNKVYSRDIFGRD

# Drug_Target_1_Reaction:
UDP-glucose + 2 NAD+ + H2O = UDP-glucuronate + 2 NADH + 2 H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the formation of UDP-glucuronic acid which is required for capsular hyaluronic acid synthesis

# Drug_Target_1_SwissProt_ID:
P0C0F4

# Drug_Target_1_SwissProt_Name:
UDG_STRPY

# Drug_Target_1_Synonyms:
EC 1.1.1.22
UDP-Glc dehydrogenase
UDP-GlcDH
UDPGDH

# Drug_Target_1_Theoretical_pI:
8.10

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01713
